DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index Subject Index Acetyl salicylic acid 64,100,106 Batroxobin 104 Acute limb ischaemia 19 Betablockers 41,46 Adenosine diphosphate (ADP) 100 Beta-thromboglobulin 28 p-Adrenoceptor agonists 106 Bifurcated graft 73 Albumin 105 Blebs 35 Alteplase, see tissue-type plasminogen Blood glucose 154 activator Blood rheology 30 Amputation Blood sugar levels 152 aetiology 88 blood tests 41 healing rate 97 Brinase 103,109 incidence 10,15,87 Buflomedil 84,97,111 indications 89,91 investigation of patients prior to 90 level of 92, 96 Calcium-antagonists 46 rates 10,15,89,96 Capillaroscopy 151 rates in diabetics 153 Capillary density 23 versus limb salvage 91 Cardiac emboli 19 Ancrod 104,109,115 Cardiac failure 25 Angiography 42,50,76,90,151 Cardiac status 20 digital subtraction 50 Cardiovascular mortality 15 Angiotensin-converting enzyme Carotid arteries 41 inhibitors 46 Catecholamine release Anistreplase 103 inhibition of 120 Ankle pressure 8,20 Cellulitis 160 Antibiotics 46,158 Cephalic vein 75 Anticoagulants 29,65,102,107,153 Cholesterol 26 Antithrombin 101 Coagulation factors 100,102 Antithrombin III 29, 101 Collagen 100 Anti-platelet drugs 28,64, 100, 106, 114, Collateral vessels 39 153 Consensus Document II 163 Anxiety 2 Consensus process 163 Aorto Iliac Disease 72 Coronary artery bypass 50 APSAC, see anistreplase 103 Coronary heart disease 45 Arterial pressure 111 Coumarin 102 Arterial spasm 21 Critical closing pressure 45 Artificial grafts 74, 77 Critical ischaemia Aspirin, see Acetyl salicylic acid assessment 41 Atherogenesis 20 biochemical factors 25 Axillo bifemoral grafts 73 clinical trial guidelines 167 170 Sachverzeichnis Critical ischaemia Factor VIII 28 definition 7,9,71,130 Factor Xa 101 epidemiology 10 Fahraeus effect 30 general management 41 Fahraeus-Lindqvist effect 30 haemodynamics 19 Fahraeus-Vejlens effect 31 incidence 10,11,163 Femoro distal procedures 75 investigation 41 Femoro-popliteal disease 74 management policy 165 Fibrin 28 pathophysiology 17, 34, 39 Fibrinogen 28, 29, 100 prognosis 12,41 Fibrinolysis Cross over graft 55,72,73 local 53,63 Crural vessel 75 Fibrinolytic agents 63 Fibronectin 100 Fluorescein angiography 23 Deep vein thrombosis 25 Fogarty catheters 73 Defibrinogenating agents 104, 109 Fontaine Denial 2 classification 8,9,71 Dependency of the feet 20 Footcare 47 Depression 2,3 Fraciparin 107 Dextran 104,110,115 Diabetes mellitus control of 154 Glycoproteins 100 incidence 146 Graft occlusion 79 prevalence 146 Graft surveillance 79 Diabetic foot clinic 160 Haematocrit 30 investigation 151, 159 Haemodilution management 152, 158, 160 normovolaemic 104,110 Diabetic osteopathy 150 Haemodynamics 18 Diabetic patient Haemoglobin 31 and critical ischaemia 11 Haemometakinesia 39 biochemical changes in 25 Heart 19 dyslipoproteinaemia in 147 Heparin 65,101,107,114 incidence of critical Hirudin 102, 108 ischaemia in 14 Hyaluronidase 109 metabolic control of 154 Hydroxyethyl starch (HES) 105 mortality 15 Hyperbaric oxygen 105, 11 0 Diabetic ulcers Hyperglycaemia 146,148 management 152 Hyperinsulinaemia 147 Dipyridamole 64, 107 Hypertension 45 Distal anastomoses 76 in diabetes 147 Diuretics 47 Hypertriglyceridaemia Doppler ankle/arm pressure index 21 in diabetes 147 Doppler sonography 151 Drug treatment 41 Duplex scanning 44, 79 Iliac disease 73 Dynamic angioplasty 59 Iliac occlusion unilateral 73 Iliac occlusions 73 Elevation test 42 bilateral 73 Endothelium 26 Iloprost Endothelium-derived constricting factor clinical trials in critical ischaemia 128 (EDCF) 26 cytoprotective effect 121 Endothelium-derived growth factor inhibition ofleukocyte activity 119 (EDGF) 26 profibrinolytic effect 120 Endothelium-derived relaxant factor protective effect on vascular endothelium (EDRF) 26,27 119 Exercise ECG 50 vasodilatory activity 119 Sachverzeichnis 171 Indanedione 102 Pain 2 Infection 46,150,159 Pallor on elevation 23 Interleukin-l 29 Papaverine test 73 Intermittent claudication 21 Pentoxifylline 84,97, 11 L Intimal hyperplasia 75 Percutaneous atherectomy 59,65 Percutaneous embolectomy 59 Percutaneous translurninal angioplasty, see Kaltenbach-Vall bracht-rotating PTA catheter 65 Peripheral neuropathy 146 Kensey-catheter 65 Peripheral resistance 77 Ketanserin 107, 111 PGE 1, see Prostaglandin E 1 Kissing-balloon method 57 Pharmacological prophylaxis 64 Pharmacotherapy 99,153 Photoplethysmography 93 Laboratory investigations 42 Placebo effect 132 Laser angioplasty 59,65 Plasma viscosity 104 Laser Doppler flowmetry 93, 158 Plasmatic capillaries 23 Laser-Doppler flux measurement 24,44, Plasmin 103 151 Plasminogen 103 Leeches 25 Plasminogen activator inhibitor type 1, Leucocytes 29,30,119 (PAI-1) 26 Limb fitting centres 88 Pilltelet activating factor (P AF) 29 Lipid Peroxides 26 Platelet activation 21 Lipids 26 Platelet refractoriness 118 Low density lipoproteins 26 Platelets 27,100 Popliteal aneurysm 70 Pressure index 158, 160 Preventive treatment Macroangiopathy 146 in diabetics 153 Magnetic resonance spectroscopy 93 Prostacyclin (PGI ) 26,27,64,96 Microangiopathy 146, 159 2 clinical studies in critical ischaemia 125 Microcirculation 18,21,43 mechanism of action 117 Microcirculatory blood flow 23,24, 35, Prostaglandin El (PGE 1) 139 clinical results in critical ischaemia 122 Microvascular defence system (MDS) 32 mechanism of action 117 Microvascular flow regulating system Prostanoids 28, 30, 84, 85,97 (MFRS) 32 antiplatelet activity 118 Mineralocortisteroids 111 clinical use 117 Monocytes 29 cytoprotective effect 121 Mortality rate 10 inhibition of catecholamine release 120 Multidisciplinaryapproach 166 inhibition ofleukocyte activity 119 Multilevel disease 39,69,72,78 interference with intimal proliferation of smooth muscle cells 121 mechanism of action 117 Naftidrofuryl 84,97, 111 "profibrinolytic" effect 120 Neuroarthropathy 150 protective effect on vascular Neuroischaemic ulcer 148, 150 endothelium 119 Neurological assessment 42 stimulatory effect of cholesterol-ester Neuropathic Ulcer 149,150 hydrolysis 121 Neutrophils 29 vasodilatoryactivity 119 Nifedipine 65 Protein C deficiency 25 Nitroglycerin 65 Pro-urokinase, see saruplase Psychological Considerations PTA Oedema 36,47 complication rates 59 Oscillography 42 contraindications 61 Oscillometric index 42 indications 59,70 172 Sachverzeichnis PTA Sympathectomy limb salvage 62 chemical 80 limiting factors 61 surgical 80 prevention of reocclusion 64 results 61 technique 59 TcP02 44,93 PTFE 74 Thermal angioplasty 59 Pulmonary embolism 25 Thermography 93 Pulsating guide wire 65 Thrombin 101 Pulse generated run-off assessment Thromboangiitis obliterans 11,85,107, (p.G.R.) 77,90 127,130 Purpura fulminans 25 Thrombocythaemia 28 Thrombolysis local 63 Thrombolytic agents 103,108,114 Radioisotope clearance 93 ThromboxaneA2 100 Rehabilitation 5,92, 97 Ticlopidine 101,106 Revisional surgery 79 Tissue-type plasminogen activator Risk factors 20,39,41,146,153 (t-PA) 26,27,63,103,114 Rubor on dependency 23,31,50 Toe systolic blood pressure 9 Run off 43,59,90 Transcutaneous oxygen measurements, see (TcP02) Transcutaneous oxygen pressure 9,23 Triglyceride 26 Saphenous vein 74,77 Saruplase 103 Segmental blood pressure measurement umbilical vein 74 21,42 Urokinase 63,75,103,108,114 Serine proteases 101 Small vessel disease 149, 159 Smoking 44 Vasomotion 24, 40 in diabetes 147 Vasomotor paralysis 22 Sodium chloride supplements 111 Veins 25 Spasm Videodensitometry 23 prophylaxis 65 Videomicroscopy 23,40 Stents 59,65 Viscosity Streptokinase 63,75,103,108,114 plasma 30 Superoxide anions 29 Vital capillary microscopy 22,23,43 Surgical reconstruction Vitamin K 102 patency rates 72,73,75 Von Willebrand factor (vWF) 26, 27, 100 .
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Syddansk Universitet Assessing Safety of Thrombolytic Therapy Kluft, Cornelis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by University of Southern Denmark Research Output Syddansk Universitet Assessing safety of thrombolytic therapy Kluft, Cornelis; Sidelmann, Johannes Jakobsen; Gram, Jørgen Brodersen Published in: Seminars in Thrombosis and Hemostasis DOI: 10.1055/s-0036-1584130 Publication date: 2017 Document version Publisher's PDF, also known as Version of record Document license Unspecified Citation for pulished version (APA): Kluft, C., Sidelmann, J. J., & Gram, J. B. (2017). Assessing safety of thrombolytic therapy. Seminars in Thrombosis and Hemostasis, 43(3), 300-310. DOI: 10.1055/s-0036-1584130 General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 12. aug.. 2017 300 Assessing Safety of Thrombolytic Therapy Cornelis Kluft, PhD1,2 Johannes J. Sidelmann, PhD2 Jørgen B. Gram, DMSc2,3 1 Good Biomarker Sciences, Leiden, The Netherlands Address for correspondence Cornelis Kluft, PhD, Good Biomarker 2 Unit for Thrombosis Research, Department of Public Health, Sciences, Zernikedreef 8, 2333 CL Leiden, The Netherlands University of Southern Denmark, Esbjerg, Denmark (e-mail: [email protected]).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Fibrinolytic Enzyme from Aspergillus Oryzae) in the Dog
    J Clin Pathol: first published as 10.1136/jcp.25.7.635 on 1 July 1972. Downloaded from Problems related to fibrinolysis 635 Thrombolytic properties and side effects of brinase (fibrinolytic enzyme from Aspergillus oryzae) in the dog WALTER H. E. ROSCHLAU From the Department ofPharmacology, University of Toronto, Ontario, Canada The thrombolytic properties of 'brinase' were in- Since the mean protease resistance of a large dog vestigated in the dog on standard 24-hour-old population was 85 TTR units with a range from 50 thrombi produced in the femoral artery and jugular to 120 TTR units, the inhibitor titre was always vein by scarification of the intima (Roschlau, 1964). measured before treatment for the prediction of a These thrombi measured about 1-5 to 2-5cmadhering systemic dose, and during an infusion for the firmly to the intima and occluding the vessels as monitoring of progressive inhibitor neutralization. confirmed by zero flow and pressure downstream Occluding arterial and venous thrombi were from the thrombus. They resembled in structure rapidly lysed within a few hours following single and composition those commonly associated with infusions of doses of brinase that reduced protease thromboembolic disease. Since spontaneous lysis did resistance to 30 TTR units (Roschlau, 1964). not occur within appropriate observation times, clot Inhibitor recovery to pretreatment levels occurred resolution after fibrinolytic treatment of the animals within 24 hours following single brinase infusions. was ascribed to the direct effects of therapy. Sustained inhibitor reduction to 40 TTR units by repeated administrations of smaller enzyme doses copyright. Systemic Administration over two to three days (Roschlau, 1965) resulted in somewhat slower but equally complete thrombo- Systemic intravenous infusions of 'brinase' were lysis.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Study Protocol
    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Antithrombotic Agents in the Management of Sepsis
    Antithrombotic Agents in the Management of Sepsis !"#$ Loyola University Medical Center, Maywood, Illinois-60153, USA ABSTRACT Sepsis, a systemic inflammatory syndrome, is a response to infection and when associated with mul- tiple organ dysfunction is termed, severe sepsis. It remains a leading cause of mortality in the critically ill. The response to the invading bacteria may be considered as a balance between proinflammatory and antiinflammatory reaction. While an inadequate proinflammatory reaction and a strong antiinflammatory response could lead to overwhelming infection and death of the patient, a strong and uncontrolled pro- inflammatory response, manifested by the release of proinflammatory mediators may lead to microvas- cular thrombosis and multiple organ failure. Endotoxin triggers sepsis by releasing various mediators inc- luding tumor necrosis factor-alpha and interleukin-1(IL-1). These cytokines activate the complement and coagulation systems, release adhesion molecules, prostaglandins, leukotrienes, reactive oxygen speci- es and nitric oxide (NO). Other mediators involved in the sepsis syndrome include IL-1, IL-6 and IL-8; arachidonic acid metabolites; platelet activating factor (PAF); histamine; bradykinin; angiotensin; comp- lement components and vasoactive intestinal peptide. These proinflammatory responses are counterac- ted by IL-10. Most of the trials targeting the different mediators of proinflammatory response have failed due a lack of correct definition of sepsis. Understanding the exact pathophysiology of the disease will enable better treatment options. Targeting the coagulation system with various anticoagulant agents inc- luding antithrombin, activated protein C (APC), tissue factor pathway inhibitor (TFPI) is a rational appro- ach. Many clinical trials have been conducted to evaluate these agents in severe sepsis.
    [Show full text]
  • Randomized, Double-Blind Study Comparing Saruplase with Streptokinase Therapy in Acute Myocardial Infarction: the COMPASS Equivalence Trial
    JACC Vol. 31, No. 3 487 March 1, 1998:487–93 CLINICAL STUDIES MYOCARDIAL INFARCTION Randomized, Double-Blind Study Comparing Saruplase With Streptokinase Therapy in Acute Myocardial Infarction: The COMPASS Equivalence Trial ULRICH TEBBE, MD, ROLF MICHELS, MD,* JENNIFER ADGEY, MD, FRCP,† JEAN BOLAND, MD,‡ AVI CASPI, MD,§ BERNARD CHARBONNIER, MD,\ JU¨ RGEN WINDELER, MD,¶ HANNES BARTH, MD,# ROBERT GROVES, PHD,# GWYN R. HOPKINS, BSC, MRCP, MFPM,# WILLIAM FENNELL, MD, FRCPI,** AMADEO BETRIU, MD,†† MIKHAIL RUDA, MD,‡‡ JOHANNES MLCZOCH, MD,§§ FOR THE COMPARISON TRIAL OF SARUPLASE AND STREPTOKINASE (COMASS) INVESTIGATORS\\ Lippe-Detmold, Bochum and Aachen, Germany; Eindhoven, The Netherlands; Belfast, Northern Ireland, United Kingdom; Lie`ge, Belgium; Rehovot, Israel; Tours, France; Cork, Ireland; Barcelona, Spain; Moscow, Russian Federation; and Vienna, Austria Objectives. This study sought to demonstrate the equivalence of Results. Death of any cause up to 30 days after randomization saruplase and streptokinase in terms of 30-day mortality. occurred in 88 (5.7%) of 1,542 patients randomized to receive Background. The use of thrombolytic agents in the treatment of saruplase and 104 (6.7%) of 1,547 patients randomized to receive acute myocardial infarction is well established and has been streptokinase (odds ratio 0.84, p < 0.01 for equivalence). Hemor- shown to substantially reduce post-myocardial infarction mortal- rhagic strokes occurred more often in patients receiving saruplase ity. (0.9% vs. 0.3%), whereas thromboembolic strokes were more Methods. Three thousand eighty-nine patients with symptoms prevalent in the streptokinase-treated patients (0.5% vs. 1.0%). compatible with those of acute myocardial infarction for <6 h The rate of bleeding was similar in the two treatment groups entered the study at a total of 104 centers and were randomized to (10.4% vs.
    [Show full text]